Clinical trials: Controlled Diabetes
Diabetic Retinopathy
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).
- Trial name
- NCT05038020
- Testing
- AKST4290
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alkahest, Inc.
Diabetes Mellitus Type 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
- Trial name
- NCT02097277
- Testing
- BMS-986036
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Diabetic Peripheral Neuropathy
A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT01087203
- Testing
- Tanezumab
- Where
- 48 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
The purposes of this study is to evaluate the efficacy and safety of SYR-472 when administered at a dose of 100 mg once weekly as an add-on to insulin therapy compared with placebo in patients with type 2 diabetes mellitus and…
- Trial name
- NCT02324569
- Testing
- SYR-472
- Where
- 65 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Primary Objective: To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin…
- Trial name
- GetGoal-Duo-2 (NCT01768559)
- Testing
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID
- Where
- 199 sites in United States, Canada and 16 more
- Volunteers
- 894 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a…
- Trial name
- NCT02738879
- Testing
- Sitagliptin, Metformin, Metformin XR
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type…
- Trial name
- NCT00455858
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin…
- Trial name
- NCT02630706
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Glycemic Control
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
- Trial name
- NCT01549964
- Testing
- Fasiglifam (TAK-875), Sitagliptin
- Where
- 160 sites in United States, Australia and 9 more
- Volunteers
- 916 people
- Sponsor
- Takeda
Diabetes Mellitus Type 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
- Trial name
- NCT01029704
- Testing
- EGT0001442
- Where
- 12 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Theracos
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company